Natixis Cuts Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Natixis cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 98.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,170 shares of the company's stock after selling 83,624 shares during the quarter. Natixis' holdings in Revolution Medicines were worth $51,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in RVMD. IFP Advisors Inc bought a new stake in shares of Revolution Medicines in the fourth quarter worth about $34,000. Sterling Capital Management LLC grew its holdings in Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after buying an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock worth $90,000 after acquiring an additional 1,613 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after acquiring an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in shares of Revolution Medicines during the 4th quarter valued at approximately $173,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RVMD has been the topic of several research reports. Stifel Nicolaus reduced their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and issued a $59.00 target price on shares of Revolution Medicines in a report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a research report on Monday. UBS Group upped their price objective on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines has an average rating of "Buy" and an average price target of $66.67.

Insider Activity at Revolution Medicines

In related news, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the sale, the chief operating officer now owns 153,533 shares of the company's stock, valued at $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This trade represents a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,660 shares of company stock valued at $650,406 over the last ninety days. 8.00% of the stock is owned by company insiders.

Revolution Medicines Stock Performance

NASDAQ RVMD traded down $0.06 on Thursday, reaching $40.32. 301,526 shares of the stock traded hands, compared to its average volume of 1,444,106. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $62.40. The company has a market cap of $7.50 billion, a price-to-earnings ratio of -11.26 and a beta of 1.37. The company has a fifty day moving average price of $37.36 and a 200-day moving average price of $43.90.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.